Tokyo, March 2, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) announced that it completed acquisition of its own shares, which was resolved by its Board of Directors on January 29, 2016, pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.
Particulars
Class of shares acquired: Common stock of the Company
Total number of shares acquired: 17,000,000 shares
Aggregate amount of acquisition cost: 27,455,199,463 yen
Period of acquisition: From February 1, 2016 to March 1, 2016
Method of acquisition: Purchased on the Tokyo Stock Exchange
(Reference)
Details of the resolution at the meeting of the Board of Directors (announced on January 29, 2016)
Class of shares to be acquired: Common stock of the Company
Total number of shares to be acquired: Up to 17 million shares
(The percentage compared to the total number of shares outstanding: 0.79%)
Aggregate amount of acquisition cost: Up to 30 billion yen
Period of acquisition: From February 1, 2016 to March 11, 2016
######
For inquiries or additional information Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201, FAX:+81-3-5201-7473
http://www.astellas.com/en
Astellas Pharma Inc. issued this content on 02 March 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 02 March 2016 02:06:19 UTC
Original Document: http://www.astellas.com/en/corporate/news/pdf/160302_En.pdf